|Clinical and Regulatory|
|Event Type:||Phase 3 Results|
This event is set for a broad date range and therefore the exact timing is unknown. This adds a degree of risk.
|Disease and Treatment|
|Treatment Name:||Metadoxine Extended Release|
Likelihood of event success varies depending on disease, treatment and lead indication classification.
The OTC BB and OTC Markets have less stringent reporting and financial requirements than the NASDAQ and NYSE. This may increase the level of risk for investors. Smaller size may have an influence on likelihood of success.
Partnerships help smaller biotech companies finance the long approval process. Partnership also provides validation the clinical program may be a worthy investment.
Detailed Event Description from Company Announcement
The company is currently enrolling patients into the MEASURE study (MDX Evaluation in Adults — Study of Response and Efficacy). The MEASURE study is the company's second Phase III study of Metadoxine Extended Release (MDX) in adults with ADHD. The study includes design and operational elements to potentially mitigate a placebo response and reduce response variability. Based on trends in recent enrollment rates, the company now expects data from the study by year end 2016.